To date, two largely mutually exclusive groups of cutaneous melanomas can be categorised: those harbouring an activating BRAF mutation (mostly BRAF V600E), which represent 40–50% of all melanoma patients, and those harbouring other mutations than BRAF [2]. This evidence concerns the gene BRAF and cutaneous melanoma.